Clinical evaluation of basic fetoprotein in bladder cancer

T. Ichikawa, Y. Nakayama, Daisuke Yamada, M. Saegusa, S. Asano, K. Aramaki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: The early diagnosis of bladder cancer allows for effective local treatment and optimizes the success of surgical therapy. Basic fetoprotein (BFP), measured using a rapid latex immuno-agglutination method, was introduced for the detection of transitional cell carcinoma. The objective of this study was to determine whether there was a correlation between urine BFP level and the grade or stage of bladder cancer, and whether the level could serve as a biochemical marker of bladder cancer. Materials and Methods: Single voided specimens were obtained from 66 patients with confirmed or suspicious bladder cancer on cystoscopy, urine cytology or BFP. Each sample was divided into 3 aliquots of which 1 was for urine analysis, 1 was tested for BFP according to latex immuno-agglutination method and 1 was sent for cytological examination. All patients subsequently under-went bladder biopsy. Results: There were 54 (82%)patients with biopsy confirmed bladder cancer and 12 (18%) with benign conditions of the bladder. Overall sensitivity with BFP and urine cytology was 38.9% and 48.1% respectively. Specificity was 58.3% and 75.0%, and positive predictive value was 80.8% and 89.7%, respectively. The positive rate of BFP and cytology was higher in invasive cancer (75% and 100%, respectively) than in superficial cancer (36% and 28%). There was no correlation between BFP level and tumor grade, while cytology had a strong association. Linear regression analysis showed the significant correlation between BFP level and tumor size (r = 0.695, p < 0.0001). The detection rate of bladder cancer was higher by the combination of BFP and cytology than by using alone. Conclusions: BFP in conjunction with urine cytology can increase the detection rate of bladder cancer. But BFP alone cannot be used as a screening test for bladder cancer.

Original languageEnglish
Pages (from-to)579-583
Number of pages5
JournalJapanese Journal of Urology
Volume91
Issue number7-8
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Fetal Proteins
Urinary Bladder Neoplasms
Cell Biology
Urine
Agglutination
Latex
Neoplasms
Urinary Bladder
Biopsy
Cystoscopy
Transitional Cell Carcinoma
Early Detection of Cancer
Linear Models

Keywords

  • BFP
  • Bladder cancer
  • Tumor marker

ASJC Scopus subject areas

  • Urology

Cite this

Ichikawa, T., Nakayama, Y., Yamada, D., Saegusa, M., Asano, S., & Aramaki, K. (2000). Clinical evaluation of basic fetoprotein in bladder cancer. Japanese Journal of Urology, 91(7-8), 579-583.

Clinical evaluation of basic fetoprotein in bladder cancer. / Ichikawa, T.; Nakayama, Y.; Yamada, Daisuke; Saegusa, M.; Asano, S.; Aramaki, K.

In: Japanese Journal of Urology, Vol. 91, No. 7-8, 2000, p. 579-583.

Research output: Contribution to journalArticle

Ichikawa, T, Nakayama, Y, Yamada, D, Saegusa, M, Asano, S & Aramaki, K 2000, 'Clinical evaluation of basic fetoprotein in bladder cancer', Japanese Journal of Urology, vol. 91, no. 7-8, pp. 579-583.
Ichikawa T, Nakayama Y, Yamada D, Saegusa M, Asano S, Aramaki K. Clinical evaluation of basic fetoprotein in bladder cancer. Japanese Journal of Urology. 2000;91(7-8):579-583.
Ichikawa, T. ; Nakayama, Y. ; Yamada, Daisuke ; Saegusa, M. ; Asano, S. ; Aramaki, K. / Clinical evaluation of basic fetoprotein in bladder cancer. In: Japanese Journal of Urology. 2000 ; Vol. 91, No. 7-8. pp. 579-583.
@article{1b08f3ebcb2e462f886dc9a936fa2bc0,
title = "Clinical evaluation of basic fetoprotein in bladder cancer",
abstract = "Purpose: The early diagnosis of bladder cancer allows for effective local treatment and optimizes the success of surgical therapy. Basic fetoprotein (BFP), measured using a rapid latex immuno-agglutination method, was introduced for the detection of transitional cell carcinoma. The objective of this study was to determine whether there was a correlation between urine BFP level and the grade or stage of bladder cancer, and whether the level could serve as a biochemical marker of bladder cancer. Materials and Methods: Single voided specimens were obtained from 66 patients with confirmed or suspicious bladder cancer on cystoscopy, urine cytology or BFP. Each sample was divided into 3 aliquots of which 1 was for urine analysis, 1 was tested for BFP according to latex immuno-agglutination method and 1 was sent for cytological examination. All patients subsequently under-went bladder biopsy. Results: There were 54 (82{\%})patients with biopsy confirmed bladder cancer and 12 (18{\%}) with benign conditions of the bladder. Overall sensitivity with BFP and urine cytology was 38.9{\%} and 48.1{\%} respectively. Specificity was 58.3{\%} and 75.0{\%}, and positive predictive value was 80.8{\%} and 89.7{\%}, respectively. The positive rate of BFP and cytology was higher in invasive cancer (75{\%} and 100{\%}, respectively) than in superficial cancer (36{\%} and 28{\%}). There was no correlation between BFP level and tumor grade, while cytology had a strong association. Linear regression analysis showed the significant correlation between BFP level and tumor size (r = 0.695, p < 0.0001). The detection rate of bladder cancer was higher by the combination of BFP and cytology than by using alone. Conclusions: BFP in conjunction with urine cytology can increase the detection rate of bladder cancer. But BFP alone cannot be used as a screening test for bladder cancer.",
keywords = "BFP, Bladder cancer, Tumor marker",
author = "T. Ichikawa and Y. Nakayama and Daisuke Yamada and M. Saegusa and S. Asano and K. Aramaki",
year = "2000",
language = "English",
volume = "91",
pages = "579--583",
journal = "Japanese Journal of Urology",
issn = "0021-5287",
publisher = "THE JAPANESE UROLOGICAL ASSOCIATION",
number = "7-8",

}

TY - JOUR

T1 - Clinical evaluation of basic fetoprotein in bladder cancer

AU - Ichikawa, T.

AU - Nakayama, Y.

AU - Yamada, Daisuke

AU - Saegusa, M.

AU - Asano, S.

AU - Aramaki, K.

PY - 2000

Y1 - 2000

N2 - Purpose: The early diagnosis of bladder cancer allows for effective local treatment and optimizes the success of surgical therapy. Basic fetoprotein (BFP), measured using a rapid latex immuno-agglutination method, was introduced for the detection of transitional cell carcinoma. The objective of this study was to determine whether there was a correlation between urine BFP level and the grade or stage of bladder cancer, and whether the level could serve as a biochemical marker of bladder cancer. Materials and Methods: Single voided specimens were obtained from 66 patients with confirmed or suspicious bladder cancer on cystoscopy, urine cytology or BFP. Each sample was divided into 3 aliquots of which 1 was for urine analysis, 1 was tested for BFP according to latex immuno-agglutination method and 1 was sent for cytological examination. All patients subsequently under-went bladder biopsy. Results: There were 54 (82%)patients with biopsy confirmed bladder cancer and 12 (18%) with benign conditions of the bladder. Overall sensitivity with BFP and urine cytology was 38.9% and 48.1% respectively. Specificity was 58.3% and 75.0%, and positive predictive value was 80.8% and 89.7%, respectively. The positive rate of BFP and cytology was higher in invasive cancer (75% and 100%, respectively) than in superficial cancer (36% and 28%). There was no correlation between BFP level and tumor grade, while cytology had a strong association. Linear regression analysis showed the significant correlation between BFP level and tumor size (r = 0.695, p < 0.0001). The detection rate of bladder cancer was higher by the combination of BFP and cytology than by using alone. Conclusions: BFP in conjunction with urine cytology can increase the detection rate of bladder cancer. But BFP alone cannot be used as a screening test for bladder cancer.

AB - Purpose: The early diagnosis of bladder cancer allows for effective local treatment and optimizes the success of surgical therapy. Basic fetoprotein (BFP), measured using a rapid latex immuno-agglutination method, was introduced for the detection of transitional cell carcinoma. The objective of this study was to determine whether there was a correlation between urine BFP level and the grade or stage of bladder cancer, and whether the level could serve as a biochemical marker of bladder cancer. Materials and Methods: Single voided specimens were obtained from 66 patients with confirmed or suspicious bladder cancer on cystoscopy, urine cytology or BFP. Each sample was divided into 3 aliquots of which 1 was for urine analysis, 1 was tested for BFP according to latex immuno-agglutination method and 1 was sent for cytological examination. All patients subsequently under-went bladder biopsy. Results: There were 54 (82%)patients with biopsy confirmed bladder cancer and 12 (18%) with benign conditions of the bladder. Overall sensitivity with BFP and urine cytology was 38.9% and 48.1% respectively. Specificity was 58.3% and 75.0%, and positive predictive value was 80.8% and 89.7%, respectively. The positive rate of BFP and cytology was higher in invasive cancer (75% and 100%, respectively) than in superficial cancer (36% and 28%). There was no correlation between BFP level and tumor grade, while cytology had a strong association. Linear regression analysis showed the significant correlation between BFP level and tumor size (r = 0.695, p < 0.0001). The detection rate of bladder cancer was higher by the combination of BFP and cytology than by using alone. Conclusions: BFP in conjunction with urine cytology can increase the detection rate of bladder cancer. But BFP alone cannot be used as a screening test for bladder cancer.

KW - BFP

KW - Bladder cancer

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=0033850505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033850505&partnerID=8YFLogxK

M3 - Article

C2 - 10965742

AN - SCOPUS:0033850505

VL - 91

SP - 579

EP - 583

JO - Japanese Journal of Urology

JF - Japanese Journal of Urology

SN - 0021-5287

IS - 7-8

ER -